Biomed completed a new round of financing
BioMed is a developer of tumor immunotherapy drugs. Its core direction is to develop innovative pharmaceutical preparations for tumor immunotherapy, which are expected to synergize with existing clinical tumor treatment technologies and significantly enhance their efficacy. At the same time, the company is still targeting Research and development of new interventional therapy technology for tumors […]
Biomed completed a new round of financing Read More »